Zhang Mingjun, Sun Qi, Yao Yisong, Chen Xi, Li Jiaxuan, Yuan Ting, Mou Yakui, Li Yumei, Song Xicheng
Qingdao Medical College, Qingdao University, Qingdao 266000, China.
Department of Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital, Yantai 264000, China.
J Immunol Res. 2025 Mar 19;2025:9375885. doi: 10.1155/jimr/9375885. eCollection 2025.
Tumor-infiltrating B cells (TILBs) are an important part of the immune response during tumor regulation. However, the significance of B cells in immunotherapy has not been fully determined. In this study, highly expressed genes in B cells were obtained by comparing the gene expression in B cells with that in other immune cells and were named TILB-mRNAs. Among them, those genes expressed in patients with head and neck squamous cell carcinoma (HNSCC) identified in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) atlas were employed to screen for genes associated with HNSCC prognosis using univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression analysis, and a TILB-related signature was constructed to predict patient prognostic risk using multivariate Cox regression analyses. The constructed TILB-related signature, which comprised seven mRNAs (, , , , , , and 7), was verified to have a good ability to predict the prognosis of patients with HNSCC using three independent validation datasets from GEO, and the predictive ability was not affected by other factors. The signature reflected the state of immune cell infiltration in tumor tissue, especially B cells, patients with higher risk scores (RSs) had fewer infiltrating immune cells in their tumors, especially B cells. The gene expression of the TILB-related signature was also verified in TILBs from HNSCC using single-cell analysis, revealing that TILB-related marker genes were differentially expressed in different GB cell subsets. This study provides risk assessment and outcome prediction for patients with HNSCC and provides potential targets for immunotherapy of HNSCC.
肿瘤浸润性B细胞(TILB)是肿瘤调节过程中免疫反应的重要组成部分。然而,B细胞在免疫治疗中的意义尚未完全确定。在本研究中,通过比较B细胞与其他免疫细胞中的基因表达,获得了B细胞中高表达的基因,并将其命名为TILB-mRNAs。其中,利用《癌症基因组图谱》(TCGA)和基因表达综合数据库(GEO)图谱中鉴定出的头颈部鳞状细胞癌(HNSCC)患者中表达的那些基因,采用单因素Cox分析、最小绝对收缩和选择算子(LASSO)回归分析筛选与HNSCC预后相关的基因,并构建了一个TILB相关特征,使用多因素Cox回归分析预测患者的预后风险。构建的包含7个mRNA(、、、、、和7)的TILB相关特征,使用来自GEO的3个独立验证数据集验证了其对HNSCC患者预后具有良好的预测能力,且预测能力不受其他因素影响。该特征反映了肿瘤组织中免疫细胞浸润的状态,尤其是B细胞,风险评分(RS)较高的患者肿瘤中浸润的免疫细胞较少,尤其是B细胞。还使用单细胞分析在HNSCC的TILB中验证了TILB相关特征的基因表达,揭示了TILB相关标记基因在不同GB细胞亚群中差异表达。本研究为HNSCC患者提供了风险评估和预后预测,并为HNSCC的免疫治疗提供了潜在靶点。